Unscheduled drug quality audits in Japan can be triggered by adverse event reports, whistleblower complaints, regulatory non-compliance, significant deviations in manufacturing processes, or discrepancies in documentation. Additionally, findings from routine inspections, media reports, or international regulatory alerts may prompt immediate audits to ensure public safety and adherence to pharmaceutical standards.